Annexure-B <u>Format for Disclosures under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011</u>

1. Name of the Target company (TC)	Dr Lal PathLabs Ltd		
Name(s) of the acquirer and Persons Acting in Concert (PAC) with the acquirer	Wasatch Advisors LP		
Whether the acquirer belongs to Promoter/Promoter group	No		
4. Name(s) of the Stock Exchange(s) where the shares of TC are Listed	BSE, NSE		
5. Details of the acquisition / disposal as follows	Number	% w.r.t. total share/voting capital wherever applicable (*)	% w.r.t. total diluted share/voting capital of the TC (**)
Before the acquisition under consideration, holding of :			
a) Shares carrying voting rights	4,302,611	5.15	5.15
b) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others)	-	-	-
c) Voting rights (VR) otherwise than by equity shares	-	-	-
d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category)	0.00	-	-
Total (a+b+c+d)	4,302,611	5.15%	5.15%

		1		<u> </u>
Details	s of acquisition/sale			
a)	Shares carrying voting rights acquired/sold	-157,500	-0.19	-0.19
b)	VRs acquired/sold otherwise than by equity shares	-	-	-
c)	Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) acquired/sold	-	-	-
d)	Shares encumbered / invoked/released by the acquirer	-	-	-
Total (a+b+c+/-d)	-157,500	-0.19%	-0.19%
After th	ne acquisition/sale, holding of:			
a)	Shares carrying voting rights	4,145,111	4.96	4.96
b)	Shares encumbered with the acquirer	-	-	-
c)	VRs otherwise than by equity shares	-	-	-
d)	Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition	-	-	-
Total (a+b+c+d)	4,145,111	4.96%	4.96%
6. Mode of acquisition / sale (e.g. open market / off-market / public issue / rights issue / preferential allotment / inter-se transfer etc).		Open market sales		
7. Date of acquisition / sale of shares / VR or date of receipt of intimation of allotment of shares, whichever is applicable.		September 13, 2024		
8. Equity share capital/ total voting capital of the TC before the said acquisition / sale.		Rs. 835,743,000 (based on par value of Rs 10.00 and total issued shares of 83,574,300)		

9. Equity share capital/ total voting capital of the TC after the said acquisition / sale.	Rs. 835,743,000 (based total issued shares of 83,574,300)
10. Total diluted share/ voting capital of the TC after the said acquisition.	83,574,300

Note:

- (*) Total share capital/ voting capital to be taken as per the latest filing done by the company to the Stock Exchange under Clause 35 of the listing Agreement.
- (**) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

Signature of the acquirer / Authorised Signatory

Dan Thurber

Dan Thurber

For and on behalf of Wasatch Advisors LP

Place : 505 Wakara Way, 3rd Floor, Salt Lake City, UT 84108 U.S.A.

Date: September 14, 2024





September 14, 2024

To, To,

Corporate Services Department, Corporate Services Department

National Stock Exchange of India Ltd.

The BSE Limited,

5th Floor, Exchange Plaza

PhirozeJeejeebhoy Towers,

Plot no. C/1, G Block,

Dalal Street,

Bandra – Kurla Complex

Mumbai-400 001

Bandra (E), Mumbai – 400 051

Ref: Scrip Code/Name: **LALPATHLAB** (NSE), **539524** (BSE)

Sub: Disclosure under Reg. 29(2) of SEBI (SAST) Regulations, 2011

Dear Sir/Madam,

With reference to the captioned subject, please find enclosed herewith the disclosure under Regulation 29(2) of SEBI (SAST) Regulation, 2011 containing details of Acquisition of Shares of Dr Lal PathLabs Ltd.

Kindly take the same on your records.

Dow the

Sincerely,

Dan Thurber

V.P., General Counsel

Wasatch Advisors LP

Acquirer

CC: Dr Lal PathLabs Ltd.